GU 2013
Interviews and expert commentary from GU 2013 — study authors and key opinion leaders discuss the findings and their clinical implications.
Audio Journal of Oncology
Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too
ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM stu
24 March 2013
0:00
Audio Journal of Oncology
Low risk localized prostate cancer: no harm from waiting!
ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Sympo
24 March 2013
0:00